摘要
目的评价替考拉宁与夫西地酸治疗耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的疗效和安全性。方法对36例应用替考拉宁和32例夫西地酸治疗的MRSA肺部感染患者进行治疗前后临床疗效、细菌清除以及不良反应统计分析,并将临床分离菌分别进行替考拉宁和夫西地酸的体外药敏试验。结果替考拉宁组对MRSA肺部感染临床有效率、细菌清除率分别为80.56%、83.33%,均高于夫西地酸组的78.13%及81.25%,但两者结果差异无统计学意义;替考拉宁组不良反应发生率为5.56%,夫西地酸组不良反应率为15.62%,两者结果差异无统计学意义;替考拉宁对两组患者痰培养所得68株MRSA均敏感,夫西地酸敏感率为95.59%。结论替考拉宁治疗MRSA肺部感染临床疗效和细菌学疗效可靠,且临床观察替考拉宁不良反应少见,MRSA肺部感染可优先选择替考拉宁。
OBJECTIVE To evaluate the efficacy and safety of teicoplanin and sodium fusidate in the treatment of patients with 1ung infection caused by methicillin-resistant Staphylococcus aureus（MRSA）.METHODS A total of 36 patients with 1ung infection with MRSA were treated with teicoplanin while,32 patients were treated with sodium fusidate.The therapeutic effect,clearance rate of pathogens,and side effects were compared.In vitro sensitivity test to two anibiotics were assayed in 68 strains of pathogens.RESULTS The clinical total effective rate,bacterial clearance rate and total adverse effects incidences of teicoplanin group were 80.56%,83.33% and 5.56% which was lower than sodium fusidate group（15.62%）.For Sodium fusidate group were 78.13%,81.25%.There was no statistical significance in results of the two groups（P0.05）.In vitro,the sensitivity test of 68 strains of pathogens showed that the sensitivity strains to teicoplanin and sodium fusidate were 100.0% and 95.59%.CONCLUSION It has high efficacy and safety so that teicoplanin can be reasonably applied and may be given the preference to the patients with lung infection with MRSA.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第15期3240-3242,共3页
Chinese Journal of Nosocomiology
